|
|
|
| home > ebr > winter 2003 > streamlining phase i through a successful partnership strategy |
|
|
 PUBLICATIONS |
European Biopharmaceutical Review
|
| The industry is under increasing pressure to streamline all phases of new drug development and significant emphasis is being placed on the ability of Phase I to identify and 'kill' unsatisfactory candidates quickly and efficiently. At the same time, this phase must arm the winners with not just safety information, but as much efficacy data as possible to help smooth the transition into later-phase clinical trials. These trends have strategic implications not only in the design of studies and programmes, but also in the organisation of R&D and selection of outsourced development partners. |
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
6th European Forum for Qualified Person for Pharmacovigilance (QPPV)
24-26 April 2012, London, UK
This event is for European qualified persons for pharmacovigilance; deputy qualified persons; senior pharmacovigilance regulators and inspectors; CROs and consultants providing QPPV services; and national responsible persons for pharmacovigilance.
More info >> |
|
 |
News and Press Releases |
 |
Record sales of new de-blistering and leak testing equipment at packaging machinery manufacturer, Sepha Ltd
The packaging machinery manufacturer, Sepha Ltd, has reported record sales of its recently extended range of non-destructive leak testing equipment for the world's pharmaceutical packaging industry. With demand up across all major markets, the company says the increase will fund future R&D and enable it to bring forward future innovations aimed at reducing costs and driving quality for pharmaceutical manufacturers and contract packers.
More info >> |
|
|
